全球磺胺类药物市场规模、份额、趋势和成长分析报告（2026-2034年）

预计磺胺类药物市场规模将从 2025 年的 1.472 亿美元成长到 2034 年的 2.327 亿美元，2026 年至 2034 年的复合年增长率为 5.22%。

磺胺类药物市场持续发展，因为这些抗菌药物在治疗人类和动物感染疾病仍然发挥着至关重要的作用。儘管新型抗生素不断涌现，但由于磺胺类药物药物价格低廉、稳定性良好且对多种细菌病原体有效，因此仍被广泛使用。其应用范围涵盖兽医学、农业和药物製剂等领域。

研究进展正推动新型磺胺类药物衍生物的开发，这些衍生物具有更优的药物动力学特性和更低的抗药性。联合治疗也在探索之中，旨在提高疗效并应对抗生素抗药性带来的新挑战。磺胺类药物的多功能性使其在药物合成中确立了基本结构和化学中间体的地位。

全球需求主要受兽药市场扩张、复方药物监管核准、农业领域持续应用等因素驱动。磺胺类药物药物市场预计将继续在全球抗生素市场中保持强劲势头，并在传统与创新之间取得平衡。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球磺胺类药物市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 外用
• 其他给药途径

第五章 全球磺胺类药物市场：依应用划分

• 市场分析、洞察与预测
• 皮肤感染疾病
• 胃肠道感染疾病（GIT感染疾病）
• 尿道感染（UTI）
• 呼吸道感染疾病（RTI）
• 其他用途

第六章 全球磺胺类药物药物市场：依药物类型划分

• 市场分析、洞察与预测
• 原药
• 学名药

第七章 全球磺胺类药物市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球磺胺类药物市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Allergan
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Bausch & Lomb Incorporated
  • Cadila Pharmaceuticals Ltd
  • Cipla Ltd
  • Dr. Reddy'S Laboratories
  • F. Hoffmann-La Roche Ltd
  • GSK PLC
  • Glenmark Pharma Ltd
  • Lexine Technochem Pvt. Ltd
  • Monarch Pharmaceuticals

The Sulphonamides Market size is expected to reach USD 232.70 Million in 2034 from USD 147.20 Million (2025) growing at a CAGR of 5.22% during 2026-2034.

The sulphonamides market continues to evolve as these antibacterial agents remain relevant in treating infections across humans and animals. Despite the availability of newer antibiotics, sulphonamides are widely used due to their affordability, stability, and effectiveness against a range of bacterial pathogens. Their application extends into veterinary medicine, agriculture, and pharmaceutical formulations.

Research is advancing the development of novel sulphonamide derivatives with improved pharmacokinetics and reduced resistance. Combination therapies are being explored to extend efficacy and address emerging antimicrobial resistance challenges. The versatility of sulphonamides also positions them as building blocks in drug synthesis and chemical intermediates.

Global demand will be supported by expanding veterinary care, regulatory approvals for combination drugs, and sustained use in agriculture. The sulphonamides market is expected to remain a resilient segment within the global antibiotic landscape, balancing tradition with innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Route Of Administration

• Oral
• Topical
• Other Routes Of Administration

By Application

• Skin Infection
• Gastrointestinal (GIT) Infection
• Urinary Tract Infection (UTI)
• Respiratory Tract Infection (RTI)
• Other Applications

By Medication Type

• Branded
• Generics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Allergan, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Bausch Lomb Incorporated, Cadila Pharmaceuticals Ltd, Cipla Ltd, Dr Reddys Laboratories, F HoffmannLa Roche Ltd, GSK PLC, Glenmark Pharma Ltd, Lexine Technochem Pvt Ltd, Monarch Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SULPHONAMIDES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Kilo Tons)

• 4.1. Market Analysis, Insights and Forecast Route Of Administration
• 4.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 4.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 4.4. Other Routes Of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 5. GLOBAL SULPHONAMIDES MARKET: BY APPLICATION 2022-2034 (USD MN and Kilo Tons)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Skin Infection Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.3. Gastrointestinal (GIT) Infection Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.4. Urinary Tract Infection (UTI) Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.5. Respiratory Tract Infection (RTI) Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 5.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 6. GLOBAL SULPHONAMIDES MARKET: BY MEDICATION TYPE 2022-2034 (USD MN and Kilo Tons)

• 6.1. Market Analysis, Insights and Forecast Medication Type
• 6.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 6.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 7. GLOBAL SULPHONAMIDES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Kilo Tons)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 8. GLOBAL SULPHONAMIDES MARKET: BY REGION 2022-2034(USD MN and Kilo Tons)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 8.2.1 By Route Of Administration
  • 8.2.2 By Application
  • 8.2.3 By Medication Type
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 8.3.1 By Route Of Administration
  • 8.3.2 By Application
  • 8.3.3 By Medication Type
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 8.4.1 By Route Of Administration
  • 8.4.2 By Application
  • 8.4.3 By Medication Type
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 8.5.1 By Route Of Administration
  • 8.5.2 By Application
  • 8.5.3 By Medication Type
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
  • 8.6.1 By Route Of Administration
  • 8.6.2 By Application
  • 8.6.3 By Medication Type
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL SULPHONAMIDES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Allergan
  • 10.2.2 Amneal Pharmaceuticals LLC
  • 10.2.3 Aurobindo Pharma
  • 10.2.4 Bausch & Lomb Incorporated
  • 10.2.5 Cadila Pharmaceuticals Ltd
  • 10.2.6 Cipla Ltd
  • 10.2.7 Dr. Reddy'S Laboratories
  • 10.2.8 F. Hoffmann-La Roche Ltd
  • 10.2.9 GSK PLC
  • 10.2.10 Glenmark Pharma Ltd
  • 10.2.11 Lexine Technochem Pvt. Ltd
  • 10.2.12 Monarch Pharmaceuticals